News
  Date Title View
Nov 20, 2017
Recently approved, non-opioid therapy now available for the management of osteoarthritis knee painLaunch of ZILRETTA commences with full complement of field sales personnel deployed across the U.S. BURLINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today ann...
Nov 17, 2017
Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project...
Nov 6, 2017
ZilrettaTM (triamcinolone acetonide extended-release injectable suspension) received FDA approval for the management of osteoarthritis (OA) knee pain on October 6, 2017Product was made commercially available on October 23, 2017, with full launch planned for late NovemberRecent equit...
Nov 2, 2017
In a pooled analysis, ZilrettaTM (triamcinolone acetonide extended-release injectable suspension) demonstrated sustained clinical improvement in knee osteoarthritis (OA) pain and function versus placebo, irrespective of baseline clinical inflammationIn an expansion of a recently published meta-analysis, Phase 2b ...
Oct 30, 2017
BURLINGTON, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its third-quarter 2017 financial results on Monday, November 6, 2017, at 4:30 p.m. ET. The dial-in numb...
Oct 11, 2017
BURLINGTON, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $25.50 per share.  The gross proceeds from this offering are expected to be approximately $122.4 milli...
Oct 10, 2017
BURLINGTON, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell 4,000,000 shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to pur...
Oct 9, 2017
Oct 6, 2017
Innovative, non-opioid, intra-articular therapy, proven to deliver meaningful analgesia over 12 weeks in patients with moderate to severe OA knee painProduct label also includes positive data from type 2 diabetes study Commercial supply expected to be available by late Octobe...
Sep 7, 2017
BURLINGTON, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today will present results from an analysis that found patients treated in clinical trials of Zilretta™ (FX006), its lead candidate for the treatment of osteoarthritis (OA) knee pain, had a statistically significantly lower use o...
1
... NextLast
= add release to Briefcase